We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Quilter Plc | LSE:QLT | London | Ordinary Share | GB00BNHSJN34 | ORD 8 1/6P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.60 | 0.41% | 147.90 | 147.40 | 148.30 | 150.80 | 146.30 | 150.80 | 1,343,618 | 16:29:58 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 4.49B | 42M | 0.0299 | 49.46 | 2.07B |
From Oct 2019 to Oct 2024
TIDMTILS TIDMQLT
RNS Number : 2626W
Tiziana Life Sciences PLC
15 April 2019
Tiziana Life Sciences plc
("Tiziana" or the "Company")
TR-1 - Notification of Major Holdings
New York/London, 15 April 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today releases the TR-1 forms appended to this announcement.
The Company understands that the resultant stake in its share capital held by Quilter plc, as nominee for certain underlying shareholders, is due to the transfer of existing shareholdings from Beaufort Securities Limited (in administration), and not due to any recent on-market purchases.
About Tiziana Life Sciences
Tiziana is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 mAbs in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
For more information go to http://www.tizianalifesciences.com
Contacts:
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder +44 (0)20 7493 2853 Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner +44 (0)20 7213 0883 Stockdale Securities (Nominated brokers) Antonio Bossi / Andy Crossley +44 (0)20 7601 6125
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
HOLUVONRKKASAAR
(END) Dow Jones Newswires
April 15, 2019 12:45 ET (16:45 GMT)
1 Year Quilter Chart |
1 Month Quilter Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
